Search fresh public links, source activity, and ready-to-use post angles for Progressive Ms.
Fresh curated links around progressive MS are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
The CONSONANCE trial was a trial of ocrelizumab De Meo E, Jolly AE, Ganzetti M, Prados Carrasco F, Kanber B, Stutters J, McManus D, Kazlauskaite A, Craveiro L, Eshaghi A, Cole J, C...
FRIDAY, May 29, 2026 — An already-approved MS drug can significantly slow progression in people with primary progressive multiple sclerosis (PPMS), according to a new study.Patien...
FRIDAY, May 29, 2026 — An already-approved MS drug can significantly slow progression in people with primary progressive multiple sclerosis (PPMS), according to a new study. Patien...
Tur C. High-efficacy therapy and progression independent of relapse and MRI activity in multiple sclerosis. Brain. 2026:awag175. https://doi.org/10.1093/brain/awag175 They say “The...
People who develop multiple sclerosis (MS) at age 50 or later are more likely to accumulate disability through mechanisms that are not directly linked to relapses or MRI activity t...
Trial in secondary progressive MS has now been reported and it failed to show a positive effect. We will have to wait for the imaging elements to surface Chataway J, Williams T, Bl...
Changes in the upper part of the spinal cord may help identify people with relapsing-remitting multiple sclerosis (RRMS) who are at higher risk of converting to the secondary progr...
What causes progression?…Many things….some we can do something about and early effective treatment is one of the them. Yep you know this already. Get diagnosed and treated. Disabil...
This study looks at cervical neck spinal cord area and say it predicts conversion to secondary progression, but I have to say prediction really, because the level of correlation is...
Scientists have identified six proteins that could serve as targets for new treatments designed to slow multiple sclerosis (MS) progression. The data showed that one protein, RRM2B...
Commonly known as MS, multiple sclerosis is a debilitating disease in which the immune system mistakenly attacks the body's nervous system. It affects around 150,000 people in the...
Abnormal fat buildup inside the brain’s immune cells may help to drive neurological damage and disability progression in people with progressive forms of multiple sclerosis (MS), a...
In a groundbreaking shift in understanding multiple sclerosis (MS), researchers from the Magnetic Resonance Imaging in MS (MAGNIMS) consortium have unveiled a transformative approa...
AB Science is stopping a late-stage clinical trial testing its oral drug masitinib as a treatment for progressive forms of multiple sclerosis (MS), saying this study and the therap...
The title says it all and you do not need me to say more….if you start on a lower efficacy treatment there is a 50-70% chance you will have disease and need another treatment, duri...
Hear it from the pulpit, on this occasion set up at The Royal Society: Disclosure (from today’s blogger): Professor Coles chairs the DMEC of ChariotMS (NCT04695080), a trial of cla...
A comprehensive study of 287 MS brain tissue donors from the Netherlands Brain Bank demonstrates that multiple sclerosis progression variability is driven by specific pathological...
Why do some multiple sclerosis patients deteriorate rapidly while others experience mild symptoms for decades? A post-mortem neuro-audit reveals that severe MS progression is linke...
No disrespect to the authours here, but when I read the title of the paper I asked what the flip does this mean? What is the Era of PIRA-A. This is an MDPI journal and so is a pay...
Tiziana Life Sciences‘ experimental nasal spray foralumab continues to show signs that it may help slow disability progression and ease fatigue in people with nonactive secondary p...
Today we welcome Dr. Daniel Vitt, CEO of Immunic Therapeutics. With World MS Day tomorrow 30th of May, this is the perfect moment to focus on multiple sclerosis. The post World MS...
Getting ocrelizumab first line offers benefits over getting ocrelizumab second line, meaning you have failed treatment. In these scenarios they are both as effective at controlling...
Scientists have uncovered a surprising clue that may help explain why multiple sclerosis (MS) progresses rapidly in some people but not others. In brain tissue from patients with s...
A new report from the National MS Society reveals that despite major advances in treatments over the last few decades, people living with multiple sclerosis (MS) still face massive...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.